Yuhuang Oral Solution Veterinary Grade API, model designation YH-OS-VG-25, is supplied as a purified multi-marker active pharmaceutical ingredient intended for further formulation into tablet, injection, capsule, powder, granule, premix, and solution dosage forms for veterinary species. The material is released against a controlled specification that includes high-performance liquid chromatography assay limits of 98.0–102.0% on the anhydrous basis, loss on drying not exceeding 5.0% per USP <731>, and heavy metals not exceeding 10 mg/kg per Ph. Eur. 2.4.8. Because the substance is manufactured under veterinary GMP with dedicated solvent recovery, residual solvent levels are controlled to USP <467> Class 3 limits. Batch-to-batch assay variance for the last three commercial batches has remained below RSD 0.8% by HPLC, while loss-on-drying variation has stayed within 0.4 percentage points. A micronized grade, designated YH-OS-VG-25F, is available where smaller particle size is required for suspension or injectable formulation.

Specification and Chemical Identity Parameters

Release testing is performed after drying and milling. The following specification applies to the general-purpose grade YH-OS-VG-25. Tighter particle-size limits apply to YH-OS-VG-25F.

Chemical identity is confirmed by Fourier-transform infrared spectrophotometry against a veterinary reference standard per USP <197> and by retention-time concordance with the principal marker in the validated HPLC method. Solubility of the dry powder is not less than 50 mg/mL in water at 25°C and not less than 30 mg/mL in ethanol at 25°C, measured by a shake-flask method. A 1% w/v aqueous solution exhibits pH 5.0–7.0. Particle size for YH-OS-VG-25 is controlled by laser diffraction per ISO 13320:2020; for YH-OS-VG-25F, D50 is 5–10 µm and D90 is ≤ 20 µm. The micronized grade is intended for injectable and suspension processes where sub-visible particulate limits per USP <788> and syringeability are relevant.

Validation of the HPLC release method for assay and related substances follows ICH Q2(R1). Linearity is established over 50–150% of the nominal test concentration, with correlation coefficient R² ≥ 0.999. Repeatability at the 100% level is below RSD 1.0% across six injections, and intermediate precision across two analysts on different days is below RSD 2.0%. Accuracy at 80%, 100%, and 120% spike levels is 98.0–102.0% recovery. System suitability requires resolution not less than 2.0 between the principal marker and the nearest co-eluting peak. These method parameters support release in veterinary GMP environments and provide the basis for the assay variability stated in the comparison table below.

In tablet, capsule, powder, and granule manufacture, the API is normally pre-blended with colloidal silicon dioxide at 0.5–1.5% w/w before high-shear granulation to reduce electrostatic adhesion and improve flow. On a 65 L high-shear granulator with impeller speed 200–300 rpm and chopper speed 1500 rpm, batch-to-batch granule size-distribution RSD remains within 6–8% when the API is added after a 3 min dry-mix step. Tablet blends containing 10–40% w/w API and 2.0–4.0% w/w croscarmellose sodium are compressed on a rotary press with 10 mm round tooling at 8.0–18.0 kN; content uniformity is tested per USP <905> and should remain below RSD 5.0%. Sticking to upper punch faces has been observed when API moisture exceeds 5.5% and magnesium stearate is used above 1.0% w/w. If ambient RH exceeds 60% during open handling, pre-drying is required because surface moisture modifies compactability.

For capsule filling on a dosator-type machine with pin compression 8–12 mm, the powder bed should exhibit Carr index 15–25% and tapped density 0.45–0.70 g/mL. If the Carr index exceeds 30%, the material is wet-granulated rather than filled directly. Dry powders and granules for oral use are passed through a 150 µm sieve after final blending; sieve cuts below this size reduce marker segregation when lactose monohydrate or dextrose is used as the carrier. Production records show that sieving after blending reduces marker RSD by approximately 2 percentage points compared with unsieved powder in multi-use packaging.

The API is supplied in 25 kg food-grade high-density polyethylene drums with double low-density polyethylene liners and desiccant. Each drum is labelled with batch number, retest date, and storage condition. For shipment in tropical zones, dry ice or phase-change packs are not used because the powder is not frozen; instead, moisture-barrier foil bags are used when ambient dew point exceeds 25°C for more than 24 h. This packaging controls moisture ingress to less than 0.5% water gain over 24 months under 25°C/60% RH. Changeover between YH-OS-VG-25 and other products on shared multi-product equipment requires cleaning validation. Residual API in rinse water is measured by HPLC after a defined cleaning cycle, with acceptance limit not more than 10 ppm of principal marker and rinse conductance below 2 µS/cm.

What Distinguishes Yuhuang Oral Solution Veterinary Grade API from Unmodified Botanical Powders?

The principal difference is specification control. Unprocessed botanical powders carry variable marker content, irregular particle geometry, higher microbial loads, and uncontrolled residual solvents. The API-grade material applies pharmacopoeial release tests to every batch, reduces heavy metals to specified limits, and controls residual solvents. The table below summarises the comparative parameters for the general-purpose grade against common feed-grade botanical powders and a representative single-chemical veterinary active.

Unlike feed-grade powder, the API is not sold as a dried herb or crude extract. It is processed to remove non-functional plant-matrix components that cause tablet capping and to reduce microbial overages that affect aqueous solution stability. This does not imply the product is sterile; sterility is obtained only after downstream injectable manufacturing. Compared with single-chemical veterinary active substances, the multi-marker profile increases analytical complexity because a marker-based HPLC specification must be used, but it also provides broader detection of botanical substitution and species-level misidentification.

When the Veterinary API Is Processed into Injectable and Premix Carriers

Injectable formulations require tighter particle control and endotoxin management. The micronized grade YH-OS-VG-25F is specified with D50 5–10 µm and is dissolved in Water for Injection at 20–25°C. The pH is adjusted to 6.0–7.5 with dilute sodium hydroxide or hydrochloric acid, and the solution is filtered through a 0.22 µm PVDF membrane under aseptic conditions in an ISO 14644-1 Class 5 cleanroom. Filter integrity is verified by bubble point before and after filtration. Endotoxin testing per USP <85> and sterility testing per USP <71> are mandatory for injectable batches. For large-volume parenterals, sub-visible particulate testing per USP <788> is applied. Terminal sterilization at 121°C for 15 min has not been validated for all marker components; published data for this specific configuration is limited, so aseptic filtration remains the standard heat-labile processing route. Solution tonicity is adjusted to 290–310 mOsm/kg with sodium chloride or dextrose. The solution is blanketed with nitrogen if headspace oxygen exceeds 2% v/v, because the marker profile is oxygen-sensitive in dilute aqueous form.

In premix production, the API is sprayed or geometrically mixed onto corncob, calcium carbonate, or defatted rice bran carriers. Ribbon mixing for 10 min at 60–70% mixer fill achieves an active-marker coefficient of variation below 5.0%. Sampling after 30 min of additional mixing provides a segregation check. Higher fill levels reduce mixing efficiency on single-shaft ribbon mixers, while fill levels below 40% may increase dust generation. Mineral oil at 0.5–1.0% w/w is used as a binder to reduce dust and improve API adherence to carrier particles. Premix batch records from commercial lines using single-shaft ribbon mixers with working volume 500–1000 L show that marker coefficient of variation remains below 5.0% when premix is sampled at 10 equidistant points after 10 min of mixing. When the same premix is conveyed through a bucket elevator, segregation increases CV by 1–3 percentage points if the powder contains particles above 500 µm. To mitigate this, the API is pre-sieved through a 150 µm mesh and the carrier is maintained below 850 µm.

In aqueous oral solution preparation, the API is dispersed in purified water containing 0.1–0.2% w/v sodium benzoate or 0.05–0.1% w/v potassium sorbate to suppress yeast and mold growth. Dissolution is performed at 25–35°C with overhead stirring at 300–500 rpm for 30–45 min. If the solution cools below 10°C, marker precipitation may occur; the formulation should be protected from freezing and from direct UV exposure. The finished solution is filtered through a 5 µm polypropylene depth filter before storage in high-density polyethylene or amber glass containers. Buffering above pH 7.5 should be avoided because marker degradation increases under alkaline aqueous conditions. Dry powder stored in tightly closed containers at ≤ 25°C and protected from light has a 24-month retest interval under VICH GL3 conditions at 25°C/60% RH and 30°C/65% RH. Aqueous solutions are not long-term stable and should be prepared within 24 h unless a formulation-specific stability study is conducted.